Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...

The collaboration between Silly Nice and CJEI is driven by a shared commitment to economic justice. As New York's cannabis ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.

Scotiabank initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm thinks the stock pullback on ...

Dyne Therapeutics Inc. (DYN) announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement ...

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a research report report published on Friday morning,Benzinga reports.

Shares of NASDAQ:DYN opened at $13.61 on Friday. Dyne Therapeutics has a 52-week low of $12.87 and a 52-week high of $47.45. The business has a fifty day moving average of $16.98 and a two-hundred ...